GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PeptiDream Inc (TSE:4587) » Definitions » Cyclically Adjusted PB Ratio

PeptiDream (TSE:4587) Cyclically Adjusted PB Ratio : 8.13 (As of Jul. 02, 2025)


View and export this data going back to 2013. Start your Free Trial

What is PeptiDream Cyclically Adjusted PB Ratio?

As of today (2025-07-02), PeptiDream's current share price is 円1575.00. PeptiDream's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was 円193.80. PeptiDream's Cyclically Adjusted PB Ratio for today is 8.13.

The historical rank and industry rank for PeptiDream's Cyclically Adjusted PB Ratio or its related term are showing as below:

TSE:4587' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 8.11   Med: 13.55   Max: 19.07
Current: 8.44

During the past years, PeptiDream's highest Cyclically Adjusted PB Ratio was 19.07. The lowest was 8.11. And the median was 13.55.

TSE:4587's Cyclically Adjusted PB Ratio is ranked worse than
86.64% of 681 companies
in the Biotechnology industry
Industry Median: 1.53 vs TSE:4587: 8.44

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

PeptiDream's adjusted book value per share data for the three months ended in Mar. 2025 was 円422.705. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is 円193.80 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


PeptiDream Cyclically Adjusted PB Ratio Historical Data

The historical data trend for PeptiDream's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PeptiDream Cyclically Adjusted PB Ratio Chart

PeptiDream Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 17.71 10.39 14.37

PeptiDream Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.50 15.47 15.49 14.37 11.23

Competitive Comparison of PeptiDream's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, PeptiDream's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PeptiDream's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PeptiDream's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PeptiDream's Cyclically Adjusted PB Ratio falls into.


;
;

PeptiDream Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

PeptiDream's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1575.00/193.80
=8.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PeptiDream's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, PeptiDream's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=422.705/111.1000*111.1000
=422.705

Current CPI (Mar. 2025) = 111.1000.

PeptiDream Quarterly Data

Book Value per Share CPI Adj_Book
201506 62.598 98.400 70.677
201509 62.894 98.500 70.939
201512 64.787 98.100 73.372
201603 79.821 97.900 90.583
201606 90.739 98.100 102.764
201609 94.695 98.000 107.353
201612 92.110 98.400 103.998
201703 91.212 98.100 103.299
201706 106.412 98.500 120.024
201709 96.626 98.800 108.655
201712 97.587 99.400 109.074
201803 94.172 99.200 105.469
201806 120.002 99.200 134.397
201809 119.570 99.900 132.975
201812 124.016 99.700 138.196
201903 124.167 99.700 138.365
201906 139.406 99.800 155.190
201909 137.936 100.100 153.094
201912 135.645 100.500 149.952
202003 132.283 100.300 146.527
202006 140.048 99.900 155.749
202009 138.392 99.900 153.907
202012 168.768 99.300 188.823
202103 170.583 99.900 189.707
202106 170.599 99.500 190.488
202109 190.740 100.100 211.700
202112 195.262 100.100 216.719
202203 190.061 101.100 208.860
202206 190.556 101.800 207.964
202209 188.501 103.100 203.128
202212 246.794 104.100 263.389
202303 245.026 104.400 260.751
202306 238.931 105.200 252.331
202309 288.539 106.200 301.852
202312 311.321 106.800 323.855
202403 308.505 107.200 319.729
202406 453.435 108.200 465.588
202409 451.114 108.900 460.227
202412 437.940 110.700 439.522
202503 422.705 111.100 422.705

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PeptiDream  (TSE:4587) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


PeptiDream Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of PeptiDream's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PeptiDream Business Description

Industry
Traded in Other Exchanges
Address
1-2-10, Nihonbashi, Chuo-ku, Toyo Building, 6th Floor, Tokyo, JPN, 103-0027
PeptiDream Inc is a biopharmaceutical company, engaged in the research and development of new pharmaceutical candidates. It discovers constrained peptides, small molecules, and peptide-drug conjugate therapeutics using its Peptide Discovery Platform System. The company aspires to be a leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide.

PeptiDream Headlines

No Headlines